Table 1: Clinicopathologic variables.
Variable |
Outcome (n = 54) |
Age at diagnosis, years (median; range) |
48 (29-79) |
Tumor size prior to treatment, cm (median; range) |
2.9 (0-13) |
Tumor size post treatment, cm (median; range) |
0.3 (0-9.9) |
Pre-treatment MRI Negative nodes Positive (enlarged/suspicious/abnormal) nodes |
6 (11.1%) 48 (88.9%) |
Post-treatment MRI Negative nodes Positive (enlarged/suspicious/abnormal) nodes |
51 (94.4%) 3 (5.6%) |
Pre-treatment Axillary Biopsy None Negative Positive |
13 (24.1%) 7 (13.0%) 34 (62.9%) |
Pre-treatment Stage I II III |
2 (3.7%) 30 (55.6%) 22 (40.7%) |
Final Pathology Stage No residual carcinoma 0 I II III |
18 (33.3%) 6 (11.1%) 8 (14.8%) 13 (24.1%) 9 (16.7%) |
Breast surgery Breast conserving surgery Mastectomy |
17 (31.5%) 37 (68.5%) |
Axillary surgery SLND SLND + ALND ALND |
13 (24.1%) 15 (27.8%) 26 (48.1%) |
Receptor status ER+/PR+/HER2- ER+/PR+/HER2+ ER-/PR-/HER2+ ER-/PR-/HER2- |
11 (23.9%) 8 (17.4%) 15 (32.6%) 12 (26.1%) |
Radiologic complete response (rCR) for breast only |
13 (24.1%) |
Receptor status of patients with rCR for breast only ER+/PR+/HER2- ER+/PR+/HER2+ ER-/PR-/HER2+ ER-/PR-/HER2- |
1 (8.3%) 4 (33.3%) 5 (41.7%) 2 (16.7%) |
Radiologic complete response (rCR) for breast & axilla |
10 (18.5%) |
Receptor status of patients with rCR for breast & axilla ER+/PR+/HER2- ER+/PR+/HER2+ ER-/PR-/HER2+ ER-/PR-/HER2- |
0 (0.0%) 3 (30.0%) 5 (50.0%) 2 (20.0%) |
Pathologic complete response (pCR) |
18 (33.3%) |
Receptor status of patients with pCR ER+/PR+/HER2- ER+/PR+/HER2+ ER-/PR-/HER2+ ER-/PR-/HER2- |
1 (5.9%) 4 (23.5%) 8 (47.1%) 4 (23.5%) |